Pay in 4 interest-free payments of $5.03 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Eli Lilly submitted the orforglipron NDA to the FDA in Q1 2026 following ATTAIN Phase 3 trial data showing 14.7% body weight reduction at 45mg positioning the worlds first oral small molecule GLP-1 receptor agonist for obesity for anticipated FDA approval in late 2026 or 2027
Both men and women benefit from GLP-1 and NAD+
Patients gave written informed consent
Medications are dispensed through our licensed partner pharmacies following a successful provider evaluation
US$ 29.15
US$ 20.80
US$ 28.38
US$ 23.90
US$ 24.23
US$ 22.20
US$ 23.15
US$ 25.78
